<DOC>
	<DOCNO>NCT02913313</DOCNO>
	<brief_summary>A study evaluate Safety Tolerability Monoclonal Antibody BMS-986207 alone Combination Nivolumab Advanced ( Solid Tumor ) Cancers</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability Monoclonal Antibody BMS-986207 Alone Combination With Nivolumab Advanced ( Solid Tumor ) Cancers</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Women men â‰¥18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Must receive progress failed one standard/approved treatment cancer type , available At least 4 week since previous treatment cancer Subject must consent pretreatment treatment tumor biopsy At least one lesion measurable disease baseline Adequate organ marrow function Patients primary brain tumor primary tumor central nervous system metastases location disease . Controlled brain metastasis permit Prior organ transplant Participants second/other active cancer require current treatment Uncontrolled/significant heart disease History chronic hepatitis , Positive test Hepatitis B virus surface antigen Hepatitis C antibody ( except participant liver cancer ) Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome ( HIV/AIDS ) Active/uncontrolled autoimmune disease Active infection Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>